About us

SmithBuildingNorth_400px-b78bc829ef277440a8ced1014d643422.jpg

An interdisciplinary research centre embedded within the Faculty of Life Sciences at The University of Manchester.

Research Themes

Screen Shot 2015-07-07 at 10.28.54-e0eb9d51e18c7d58d53f291ee447a9c6.png

Vision: To determine the mechanisms underpinning how cell-matrix interactions control normal tissue formation and function, and how their disruption causes disease. 

For everyone

Screen Shot 2015-05-13 at 08.41.48-bd8b3b5678cec2e83e4d17f6d5966fa1.png

Learn all about the Immortality exhibition, a art-science collaboration between Sally Gilford and the Centre, on YouTube Read more

Our discoveries

Our core facilities

Our public engagement activities

Our research

Our publications

Latest News

images-3cfac337cfe531357a26654490dcc0ba.jpeg

Grants awarded:    Tom Jowitt and Rachel Lennon (with Paul Brenchley and Edward Mckenzie), Kidney Research UK, August 2015-August 2018. Blocking PLA2R receptor activation on podocytes with soluble epitope peptide can modulate the pathological effects of anti-PLA2R:  a new therapy for preventing relapse in membranous nephropathy Read more

Upcoming events

GC5-Final-poster-300315-6970bf1f230b7d40ab420ccfb655fa17.jpg

'Get Connected’ the annual conference of the Wellcome Trust Centre for Cell-Matrix Research, will be held 16-18 September 2015 and is based on the Chrono-Matrix theme and is entitled Timing, timing, timing: the dynamics of cell-matrix interaction Read more

Latest Discoveries

 
zebrafish-789c3e2bdc24de024859750037eb3122.png

Melanoma is the most deadly form of skin cancer because melanoma cells are highly invasive and spread easily. It was always thought that melanoma cells can be divided into invasive and non-invasive cells, and that these properties can be extrapolated to a whole tumour.  Read more

immune cells (red) in a tumour -054a58d9e6f1f73ec82d46d89397d0f3.jpg

Melanoma is the most deadly form of skin cancer with around 13,300 people diagnosed in the UK each year. Recently novel ‘targeted’ therapies using small molecule inhibitors have been developed, which are very effective in a large group of patients. Unfortunately, patients often stop responding at some point, because they develop resistance to these novel targeted drugs. Read more